Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial

Pain

Volumn 133, Issue 1-3, 2007, Pages 210-220

  Nurmikko, Turo J ^a   Serpell, Mick G ^b   Hoggart, Barbara ^c   Toomey, Peter J ^d   Morlion, Bart J ^e   Haines, Derek ^f  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^c SOLIHULL HOSPITAL   (United Kingdom)

^d YORK HOSPITAL   (United Kingdom)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

Allodynia; Cannabinoid; Peripheral neuropathic pain; Sativex

Indexed keywords

CANNABIS; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ALLODYNIA; ANALGESIC ACTIVITY; ANOREXIA; ARTICLE; ATTENTION DISTURBANCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG WITHDRAWAL; DRUNKENNESS; EYELID EDEMA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MULTICENTER STUDY; NAUSEA; NEUROPATHIC PAIN; NOCICEPTION; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINOPHARYNGITIS; SEDATION; SIDE EFFECT; SOMNOLENCE; SYMPTOM; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URTICARIA; VISUAL ANALOG SCALE; VOMITING; XEROSTOMIA;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; AGED; ANALGESICS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERESTHESIA; MALE; MIDDLE AGED; NEURALGIA; PAIN MEASUREMENT; PERIPHERAL NERVOUS SYSTEM DISEASES; PLANT EXTRACTS; PSYCHOMOTOR PERFORMANCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 36348982602     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2007.08.028     Document Type: Article

References (40)

1. Abrams D.I., Jay C.A., Shade S.B., Vizoso R.N., Reda H., Press S., et al. Cannabis in painful HIV-associated sensory neuropathy. A randomised placebo-controlled trial. Neurology 68 (2007) 515-521
2. Attal N., Cruccu G., Haanpää M., Hansson P., Jensen T.S., Nurmikko T., et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 11 (2006) 1153-1169
3. Attal N., Rouaud J., Brasseur L., Chauvin M., and Bouhassira D. Systemic lidocaine in pain due to peripheral nerve injury and predictors of response. Neurology 62 (2004) 218-225
4. Backonja M.A., Beydoun A., Edwards K.R., Schwartz S.L., Fonseca V., Hes M., et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 280 (1998) 1831-1836
5. Banks M.H. Validation of the General Health Questionnaire in a young community sample. Psychol Med 13 (1983) 349-353
6. Berman J.S., Symonds C., and Birch R. Efficacy of cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomized controlled trial. Pain 112 (2004) 299-306
7. Bever Jr. C.T., Grattan L., Panitch P.H., and Johnson K.P. The Brief Repeatable Battery of Neuropsychological Tests for Multiple Sclerosis: a preliminary serial study. Mult Scler 1 (1995) 165-169
8. Costa B., Giagnoni G., Franke C., Trovate A.E., and Colleani M. Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br J Pharmacol 143 (2004) 247-250
9. Farrar J.T., Young J.P., La Moreaux L., Werth J.L., and Poole R.M. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94 (2000) 149-158
10. Galer B.S., and Jensen M.P. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology 48 (1997) 28-33
11. Goldberg D.P., Gater R., Sartorius N., Ustun T.B., Piccinelli M., Gureje O., et al. The validity of two versions of the GHQ in the WHO study of mental illness in general health care. Psychol Med 27 (1997) 191-197
12. Gilron I., Bailey J.M., Tu D., Holder R., Weaver D.F., and Houlder R.L. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 352 (2005) 1324-1334
13. Guy G.W., and Flint M.E. A single centre, placebo-controlled, four period, crossover, tolerability study assessing pharmacokinetic effects, pharmacokinetic characteristics and cognitive profiles of as single dose of three formulations of cannabis based medicine extracts (CBMEs) plus a two period tolerability study comparing pharmacodynamic effects and pharmacokinetic characteristics of a single dose of a cannabis based medicine extract given via two administration routes. J Cannab Ther 3 (2003) 35-77
14. Guy G.W., and Robson P. A Phase I, a double blind, three-way crossover study to assess the pharmacokinetic profile of cannabis based medicine extract (CBME) administered sublingually in variant cannabinoid ratios in normal healthy male volunteers. J Cannab Ther 3 (2003) 121-152
15. Herzberg U., Eliav E., Bennett G.J., and Kopin I.J. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett 221 (1997) 157-160
16. Iskedijan M., Bereza B., Gordon A., Piwko C., and Einarson T.R. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis pain. Curr Med Res Opin 23 (2007) 17-24
17. Jensen T.S. Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain 6 Suppl A (2002) 618
18. Jones R.T. Cardiovascular system effects of marijuana. J Clin Pharmacol 42 (2002) 58S-63S
19. Karst M., Salim K., Burstein S., Conrad I., Hog C., and Schneider U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain. JAMA 290 (2003) 1757-1762
20. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
21. Meier T., Wassner G., Faust M., Kuntzner T., Ochsner F., Hueppe M., et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled trial. Pain 106 (2003) 151-158
22. Nahas G.G., Schwartz I.W., Adamec J.M., and Manger W.M. Tolerance of delta 9 THC in the spontaneously hypertensive rat. Proc Soc Exp Biol Med 142 (1973) 58-60
23. Nikolasjen L., Gotrup H Kristensen A.G., and Jensen T.S. Memantine (a N-methyl-d-aspartate receptor antagonist) in the treatment of neuropathic pain after amputation or surgery: a randomized, double-blind, cross-over study. Anesth Analg 91 (2000) 960-966
24. Pevalin D.J. Multiple applications of the GHQ-12 in a general population sample: an investigation of long-term retest effects. Soc Psychiatry Psychiatr Epidemiol 35 (2000) 508-512
25. Rice A.S., and Maton S. Gabapentin in postherpetic neuralgia: a randomised, double-blind, placebo-controlled study. Pain 94 (2001) 215-224
26. Rog D.J., Nurmikko T.J., Friede T., and Young C.A. Randomized Controlled Trial of Cannabis Based Medicine in Central Neuropathic Pain due to Multiple Sclerosis. Neurology 65 (2005) 812-819
27. Russo E.B., and McPartland J.M. Cannabis is more than simply Delta(9)-tetrahydrocannabinol. Psychopharmacology (Berl) 165 (2003) 431-432
28. 2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats. Eur J Neurosci 22 (2005) 371-379
29. Serpell M.G. Neuropathic Pain Study Group. Gabapentin in neuropathic pain syndrome: a double-blind, placebo-controlled trial. Pain 99 (2002) 557-566
30. Svendsen K.B., Jensen T.S., and Bach F.W. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. Br Med J 329 (2004) 25-38
31. Tait R.C., Chibnall J.T., and Krause S. The Pain Disability Index: psychometric properties. Pain 40 (1990) 171-182
32. Varvel S.A., Wiley J.L., Yang R., Bridgen D.T., Lomg K., Lichtman A.H., et al. Interactions between THC and cannabidiol in mouse models of cannabinoid activity. Psychopharmacology 186 (2006) 226-234
33. Wade D.T., Makela P., Robson P., House H., and Bateman C. Do cannabis-based medicinal extracts have general or specific effects in multiple sclerosis? A double-blind, randomised, placebo-controlled study on 160 patients. Mult Scler 10 (2004) 434-441
34. Wallace M., Braun J., and Schulters G. Postdelivery of alfentanil and ketamine has no effect on intradermal capsaicin induced pain and hyperalgesia. Clin J Pain 18 (2002) 373-379
35. Wallace M.S., Magnusson S., and Ridgeway B. Efficacy of oral mexiletine for neuropathic pain: a double-blind, placebo-controlled, cross-over study. Reg Anesth Pain Med 25 (2000) 459-467
36. Wallace M.S., Rowbotham M.C., Katz N.P., Dworkin D.H., Dotson R.M., Galer B.S., et al. A randomized, double-blind, placebo-controlled trial of glycine antagonist in neuropathic pain. Neurology 59 (2002) 1694-1700
37. Werneke U., Goldberg D.P., Yalsin I., and Ustun B.T. The stability of the factor structure of the General Health Questionnaire. Psychol Med 30 (2000) 823-829
38. Witkin J.M., Tzavara E.T., and Nomikos G.G. A role for cannabinoid CB1 receptors in mood and anxiety disorders. Behav Pharmacol 16 (2005) 315-331
39. Woolf C.J. Dissecting out mechanisms responsible for peripheral neuropathic pain: implications for diagnosis and therapy. Life Sci 74 (2004) 2605-2610
40. Zajisec J., Fox P., Sanders H., Wright D., Vickery J., Nunn A., et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 363 (2003) 1517-1526